Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Jakub Kaczor | Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning with Lumanity’s Jaku..., Sonic AI
Home
/
Outcomes Rocket
/
Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning with Lumanity’s Jaku...
Outcomes Rocket
Notify me
•
Jul 9, 2026
•
22:41
Interview
Playing Nicely with Friends: How to Make Choices on Portfolio Co-positioning with Lumanity’s Jaku...
From
Outcomes Rocket
Saul Marquez
(Host)
•
Saul
(Host, Outcomes Rocket)
•
Peter Smith
(Guest)
•
Jakub Kaczor
(Vice President, Lumanity)
Get the full transcript next time Outcomes Rocket releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Pharmaceutical companies with focused R&D strategies often create products that compete internally, sub-optimizing the portfolio's commercial potential.
The looming patent cliff, threatening $300 billion in revenue by 2030, intensifies the pressure on pharma companies to maximize the value of their entire product portfolio.
Effective co-positioning must begin early in clinical development, not at launch, to strategically influence patient targeting, endpoint selection, and label language for clear differentiation.
Organizational alignment is critical for success; this requires a collaborative mindset, clear portfolio ownership, and incentives based on portfolio-wide performance to overcome individual 'brand ego'.
Continue your research
Keep pulling the thread on Jakub Kaczor.
The Paradox of R&D Focus
Organizational Alignment as the Linchpin for Success
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed Jul 9, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini